Ataluren Treatment Benefits Some nmCF Patients in Phase 3 Trial from PTC Therapeutics

PTC Therapeutics, Inc. announced unexpected, yet encouraging results of their product ataluren. The biopharmaceutical company focuses on developing small-molecule drugs that target post-transcriptional control processes to alter protein production. Ataluren is PTC’s investigational new drug designed to restore protein function in cystic fibrosis patients with a nonsense mutation (nmCF)…

Cystic Fibrosis Foundation’s Peppermint Oil in Nebulizers Warning Well-Founded, But Teen Researcher’s Findings Merit Further Investigation

Complimentary therapeutic approaches are nothing if not controversial in conventional medicine and mainstream organizations offering information and support for those afflicted with particular diseases. This leaning toward cautious conservatism is commendable, as there is usually plenty of unsubstantiated advice around — often associated with the sale of scientifically unproven…

Cystic Fibrosis Drug Developer Vertex Pharmaceuticals To Present at UBS Global Healthcare Conference On May 20th

Vertex Pharmaceuticals, Inc., an international biotech company that has recently been making significant progress in clinical phase research geared towards combating cystic fibrosis, has just announced that they will be presenting during the UBS Global Healthcare Conference. The conference is scheduled to take place at the Sheraton New York Hotel…

What Do Microwave Popcorn And Cystic Fibrosis Have In Common?

San Diego State University postdoctoral researcher Katrine Whiteson, Ph. D. has found that a molecule previously linked to lung injuries in factory workers producing microwave popcorn might also play an important role in microbial lung infections suffered by people with cystic fibrosis (CF). The molecule, known as 2,3-butanedione, which tastes “buttery” and…

Rutgers’ Cystic Fibrosis Center Granted Quality Care Award

The Cystic Fibrosis Foundation (CFF) has just given its sought-after Quality Care Award for 2012-2013 to The Cystic Fibrosis Center of Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital. Established back in 2008, the Foundation’s Quality Care Award served to give due recognition to cystic fibrosis (CF) centers that…

PUR0400 Drug Formulation For Cystic Fibrosis (CF), non-CF Bronchiectasis Shows Promise In Recent Trial

Lexington, Massachusetts-based Pulmatrix made an impact at the 2014 Respiratory Drug Delivery Conference being held in Fajardo, Puerto Rico. A poster from the biotechnology company presented data related to PUR0400 (fluoroquinilone Levofloxac), a preclinical drug candidate formulated using Pulmatrix’s proprietary iSPERSE™ dry powder technology. PUR0400 is a drug formulation that…

Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.